Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Endothelial pyruvate kinase M2 maintains vascular integrity
Boa Kim, … , Kristina Li, Zolt Arany
Boa Kim, … , Kristina Li, Zolt Arany
Published September 17, 2018
Citation Information: J Clin Invest. 2018;128(10):4543-4556. https://doi.org/10.1172/JCI120912.
View: Text | PDF
Research Article Metabolism Vascular biology

Endothelial pyruvate kinase M2 maintains vascular integrity

  • Text
  • PDF
Abstract

The M2 isoform of pyruvate kinase (PKM2) is highly expressed in most cancer cells, and has been studied extensively as a driver of oncogenic metabolism. In contrast, the role of PKM2 in nontransformed cells is little studied, and nearly nothing is known of its role, if any, in quiescent cells. We show here that endothelial cells express PKM2 almost exclusively over PKM1. In proliferating endothelial cells, PKM2 is required to suppress p53 and maintain cell cycle progression. In sharp contrast, PKM2 has a strikingly different role in quiescent endothelial cells, where inhibition of PKM2 leads to degeneration of tight junctions and barrier function. Mechanistically, PKM2 regulates barrier function independently of its canonical activity as a pyruvate kinase. Instead, PKM2 suppresses NF-kB and its downstream target, the vascular permeability factor angiopoietin 2. As a consequence, loss of endothelial cell PKM2 in vivo predisposes mice to VEGF-induced vascular leak, and to severe bacteremia and death in response to sepsis. Together, these data demonstrate new roles of PKM2 in quiescent cells, and highlight the need for caution in developing cancer therapies that target PKM2.

Authors

Boa Kim, Cholsoon Jang, Harita Dharaneeswaran, Jian Li, Mohit Bhide, Steven Yang, Kristina Li, Zolt Arany

×

Figure 4

Glycolysis is impaired in PKM2 knockdown ECs.

Options: View larger image (or click on image) Download as PowerPoint
Glycolysis is impaired in PKM2 knockdown ECs.
(A) Extracellular acidific...
(A) Extracellular acidification rate (ECAR) of HUVECs with si-control/scrambled RNA (siC) versus siPKM2 in the absence and presence of oligomycin (Oligo) demonstrating basal and maximal glycolytic rate, respectively (n = 8). (B) Relative abundance of glycolysis intermediates in HUVECs with siC versus siPKM2 were quantified by mass spectrometry after 24 hours of incubation (n = 3). (C) Pyruvate kinase activity of HUVECs with siC versus siPKM2 (n = 6). (D) PDH activity estimated by incorporation of [U-13C] glucose–derived carbons into M+2 citrate, αKG, and aspartate in HUVECs with siC versus siPKM2 (n = 3). (E) Pyruvate carboxylase (PC) activity estimated by incorporation of [U-13C] glucose–derived carbons into M+5 citrate (n = 3). (F) Relative abundance of TCA cycle intermediates in HUVECs with siC versus siPKM2 were quantified by mass spectrometry after 24 hours of incubation (n = 3). (G) Oxygen consumption rate (OCR) of HUVECs with siC versus siPKM2 was measured by Seahorse (n = 8). All data are mean ± SD. *P < 0.05, **P < 0.01, by 2-tailed Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts